Literature DB >> 23023232

HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells.

Stefania Mardente1, Emanuela Mari, Fabrizio Consorti, Cira Di Gioia, Rodolfo Negri, Marilena Etna, Alessandra Zicari, Alfredo Antonaci.   

Abstract

Experimental and epidemiological studies have revealed that chronic inflammation contributes to cancer progression and even predisposes to cellular transformation. Inflammatory infiltrates in papillary thyroid cancer include lymphocytes, macrophages and cytokines. High-mobility group box 1 protein (HMGB1) is a late inflammatory cytokine that signals danger to the immune system through the receptor for advanced glycation end-products (RAGE) and Toll-like receptor. The activation of the above receptors results in the secretion of growth, chemotactic and angiogenic factors that contribute to chronic inflammation. In this study, we suggest that apart from the activation of signal transduction pathways by the activation of RAGE, the indirect inhibition of cell cycle regulators [such as phosphatase and tensin homolog (PTEN)] may also cause an increase in cell growth and motility. MicroRNAs (miRNAs) have increasingly been implicated in regulating the malignant progression of cancer. MiR-221 and miR-222 have been found to be deregulated in human papillary thyroid carcinomas. They are involved in cell proliferation through the inhibition of the cell cycle regulator, p27kip1, in human papillary carcinomas. In this study, we show that HMGB1 increases the expression of miR-221 and miR-222 in primary cultures of excised papillary lesions and in an established papillary cancer cell line (BC PAP). The overexpression of oncogenic miR-221 and miR-222 caused by HMGB1 is associated with an increase in malignancy scores, namely cell growth and motility.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23023232     DOI: 10.3892/or.2012.2058

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  33 in total

1.  High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity.

Authors:  Man Chen; Yao Liu; Patrick Varley; Ying Chang; Xing-Xing He; Hai Huang; Daolin Tang; Michael T Lotze; Jusheng Lin; Allan Tsung
Journal:  Cancer Res       Date:  2015-02-26       Impact factor: 12.701

Review 2.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

3.  Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis.

Authors:  Ruiguang Zhang; Yan Li; Zhongliang Wang; Lingjuan Chen; Xiaorong Dong; Xiu Nie
Journal:  Tumour Biol       Date:  2015-06-04

4.  miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3.

Authors:  Rui Li; Jia Liu; Qun Li; Guang Chen; Xiaofang Yu
Journal:  Tumour Biol       Date:  2015-10-19

5.  Action of HMGB1 on miR-221/222 cluster in neuroblastoma cell lines.

Authors:  Emanuela Mari; Alessandra Zicari; Flavia Fico; Isabella Massimi; Lolli Martina; Stefania Mardente
Journal:  Oncol Lett       Date:  2016-07-18       Impact factor: 2.967

Review 6.  HMGB1 in hormone-related cancer: a potential therapeutic target.

Authors:  Madhuwanti Srinivasan; Souresh Banerjee; Allison Palmer; Guoxing Zheng; Aoshuang Chen; Maarten C Bosland; André Kajdacsy-Balla; Ramaswamy Kalyanasundaram; Gnanasekar Munirathinam
Journal:  Horm Cancer       Date:  2014-04-10       Impact factor: 3.869

7.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

Review 8.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

9.  Glycyrrhizin Protects γ-Irradiated Mice from Gut Bacteria-Associated Infectious Complications by Improving miR-222-Associated Gas5 RNA Reduction in Macrophages of the Bacterial Translocation Site.

Authors:  Ichiaki Ito; Bradford D Loucas; Sumihiro Suzuki; Makiko Kobayashi; Fujio Suzuki
Journal:  J Immunol       Date:  2020-01-15       Impact factor: 5.422

10.  Survival of Mice with Gastrointestinal Acute Radiation Syndrome through Control of Bacterial Translocation.

Authors:  Fujio Suzuki; Bradford D Loucas; Ichiaki Ito; Akira Asai; Sumihiro Suzuki; Makiko Kobayashi
Journal:  J Immunol       Date:  2018-05-09       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.